Medical Monitoring Without Present Injury

Surveillance as the Injury, or No Injury at All: The Medical-Monitoring Split

The federal anchor frames the whole survey. Metro-North Commuter Railroad v. Buckley, 521 U.S. 424 (1997) held that an asbestos-exposed railroad worker "cannot recover unless, and until, he manifests symptoms of a disease": the "physical impact" that unlocks tort recovery "does not include a simple physical contact with a substance that might cause a disease at a substantially later time," and the asymptomatic worker’s demand for monitoring costs failed because the Court did "not find sufficient support in the common law for the unqualified rule of lump-sum damages recovery" he pressed. Buckley construed the FELA, not state law — so the state high courts have spent three decades answering the question for themselves, and they have split.

The recognizing line treats the need for surveillance itself as the compensable harm. Potter v. Firestone Tire & Rubber Co., 6 Cal. 4th 965 (Cal. 1993) holds that monitoring costs "are a compensable item of damages in a negligence action where the proofs demonstrate, through reliable medical expert testimony, that the need for future monitoring is a reasonably certain consequence of the plaintiff’s toxic exposure and that the recommended monitoring is reasonable," measured by factors including "the toxicity of the chemicals," "the seriousness of the disease for which the plaintiff is at risk," and "the clinical value of early detection and diagnosis." Bower v. Westinghouse Electric Corp., 522 S.E.2d 424 (W. Va. 1999) went further and recognized a freestanding claim — "a cause of action exists under West Virginia law for the recovery of medical monitoring costs, where it can be proven that such expenses are necessary and reasonably certain to be incurred as a proximate result of a defendant’s tortious conduct" — built on significant exposure, "an increased risk of contracting a serious latent disease," and the need for "periodic diagnostic medical examinations different from what would be prescribed in the absence of the exposure." Massachusetts split the difference with a physiological hook: Donovan v. Philip Morris USA, Inc., 914 N.E.2d 891 (Mass. 2009) holds that "[w]hen competent medical testimony establishes that medical monitoring is necessary to detect the potential onset of a serious illness or disease due to physiological changes indicating a substantial increase in risk of harm from exposure to a known hazardous substance, the element of injury and damage will have been satisfied and the cost of that monitoring is recoverable in tort," and that "[n]o particular level or quantification of increase in risk of harm is necessary, so long as it is substantial and so long as there has been at least a corresponding subcellular change."

The rejecting line holds the traditional gate. Henry v. Dow Chemical Company, 701 N.W.2d 684 (Mich. 2005) — a dioxin-exposure class action — "reaffirm[ed] the principle that a plaintiff must demonstrate a present physical injury to person or property in addition to economic losses that result from that injury in order to recover under a negligence theory," because "[a] financial ‘injury’ is simply not a present physical injury, and thus not cognizable under our tort system"; as the court clarified, a medical monitoring claim "does not exist in Michigan." Caronia v. Philip Morris USA, Inc., 22 N.Y.3d 439 (N.Y. 2013) answered the Second Circuit’s certified question the same way: "[t]he requirement that a plaintiff sustain physical harm before being able to recover in tort is a fundamental principle of our state’s tort system," "[a] threat of future harm is insufficient to impose liability against a defendant in a tort context," and monitoring "is an element of damages that may be recovered only after a physical injury has been proven, i.e., that it is a form of remedy for an existing tort." The PFAS wave has so far reinforced rather than eroded that line — Brown v. Saint-Gobain Performance Plastics Corp., 300 A.3d 949 (N.H. 2023), a certified question out of PFOA groundwater litigation, held that "the mere existence of an increased risk of future development of disease is not sufficient under New Hampshire law to constitute a legal injury for purposes of stating a claim for the costs of medical monitoring as a remedy or as a cause of action in the context of plaintiffs who were exposed to a toxic substance but have no present physical injury," reasoning that "an increased risk of harm is not an injury for purposes of a negligence action."

The survey is really three columns, not two. Before filing, place the forum: exposure-plus-increased-risk states on the Potter and Bower line, physiological-marker states built on Donovan’s subcellular change, and manifest-injury states holding with Henry, Caronia, and Brown — and confirm whether the jurisdiction treats monitoring as an element of damages on an existing tort or as a freestanding claim, because that choice controls pleading, class certification, and when the limitations clock starts. In marker states, build the biomarker record early; blood-serum testing can convert exposure-only plaintiffs into plaintiffs with a cognizable injury. And watch the legislatures: the rejecting courts consistently describe the question as policy for lawmakers, so statutory monitoring remedies and fresh certified questions — not common-law drift — are where the map is most likely to move next.